eGain Expects FY21 Results To Top Guidance, Consensus

eGain Corp (NASDAQ:EGAN) expects FY21 revenue and earnings to be at or above the high end of its previously provided guidance range. The…
  • eGain Corp (NASDAQ:EGAN) expects FY21 revenue and earnings to be at or above the high end of its previously provided guidance range.
  • The company had expected revenue of $77.3 million to $77.9 million, versus the analyst consensus of $76.34 million.
  • It expected SaaS revenue of $66 million to $66.4 million.
  • It estimated non-GAAP net income of  $6.2 million to $7.1 million, GAAP net income of $4.4 million to $5.3 million, or $0.13 to $0.16 per share.
  • The company’s non-GAAP EPS guidance was $0.19 to $0.22, compared to the analyst consensus of $0.15.
  • It expects to end FY21 with $63 million in cash and no debt.
  • Price action: EGAN shares closed lower by 1.54% at $10.89 on Wednesday.
Total
0
Shares
Related Posts
Read More

Merck Announces U.S. FDA Has Granted Breakthrough Therapy Designation For V116, the Company’s Investigational 21-Valent Pneumococcal Conjugate Vaccine, For The Prevention Of Invasive Pneumococcal Disease And Pneumococcal Pneumonia In Adults

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that V116, the company's investigational 21-valent pneumococcal conjugate vaccine, has received Breakthrough Therapy Designation

MRK